Genentech, Inc.

F. Hoffmann-la Roche Ag

Dhaya Seshasayee

Meredith C Hazen

Menno Van Lookeren Campagne

Gerald R Nakamura

Jack Bevers, Iii

Yi-Chun Hsiao

Hongkang Xi

Yan Wu

Wei-Ching Liang

Philip E Hass

Wenwu Zhai

Nancy Chiang

Rajita Khosla

Jane Louise Grogan

Zhonghua Lin

Robert J Johnston

Mahesh Yadav

Isidro Hotzel

Joseph R Arron

Laetitia Comps-Agrar

Benny Chih

Tiffany Wong

Tulika Tyagi

Daryle Depianto

Thirumalai Rajan Ramalingam

Wendy Green Halpern

Jian Ping Yin

Jia Wu

Tianhe Sun

David Verne Hansen

Ainhoa Echeverria Larraza

WeiYu Lin

Racquel Corpuz

Hiu Nam Chan

Jane L Grogan

Meredith Hazen

Jack Iii Bevers

The instant technology generally relates to improved methods for producing antibodies, antibody libraries, hybridomas, hybridoma libraries, etc. For example, these methods increase the number of antigen-specific B cells produced, increase the number of hybridomas, and/or increase the number of monoclonal antibodies that can be made in a given production cycle.

Developing an efficient hybridoma platform for therapeutic antibody discovery

This application discloses, inter alia, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50 pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2. In some embodiments, antibodies herein also inhibit shedding of soluble TREM2 in a human microglia cell model and in vivo in a mouse model, decrease levels of soluble TREM2 in plasma, CSF and/or the brain, enhance survival of human microglia cells, and increase Aβ plaque formation and compaction in a human microglia model (for example, as measured by increased Aβ plaque intensity and/or increased X04 plaque intensity in human microglia), and thus, may provide a number of neuroprotective activities.

Agonists of TREM2

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.

Isoform-selective anti-TGFβ antibodies and methods of use

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Anti-TIGIT antibodies and methods of use

Anti-tigit antibodies and methods of use

Growing community of inventors

Cupertino, CA, United States of America

Dhaya Seshasayee